세계의 RNA 기반 치료제 및 백신 시장 : 제품 유형별, 최종 사용자별, 지역별 - 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has conducted a thorough analysis of the RNA-based Therapeutics and Vaccines Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the RNA-based Therapeutics and Vaccines Market spanning from 2024 to 2031.

The global RNA-based therapeutics and vaccines market surged with hitting US$201.95 Mn by 2024. Forecasts anticipate a staggering 86.6% CAGR between 2024 and 2031, reaching US$4568.88 Mn.

Key Insights:

• RNA-based Therapeutics and Vaccines Market Size (2024): US$201.95 Mn
• Projected Market Value (2031): US$4568.88 Mn
• Global Market Growth Rate (CAGR 2024-2031): 86.6%

RNA-based Therapeutics and Vaccines Market - Report Scope

The scope of the RNA-based therapeutics and vaccines market report encompasses a comprehensive analysis of the global landscape, spanning from 2024 to 2031. It delves into the market dynamics, including drivers, challenges, and opportunities, while examining key trends influencing growth. The report provides detailed segmentation based on product type, application, end-user, and geography, offering insights into market size, share, and forecast figures. Additionally, it evaluates competitive scenarios, profiling key players and their strategies, alongside regulatory frameworks shaping the industry. This comprehensive scope aims to equip stakeholders with actionable intelligence for informed decision-making in the RNA-based therapeutics and vaccines market.

Market Growth Drivers

Several factors are driving the remarkable growth of the RNA-based therapeutics and vaccines market. Firstly, advancements in biotechnology and molecular biology have paved the way for the development of innovative RNA-based treatments and preventive measures. Additionally, the increasing prevalence of chronic diseases and infectious outbreaks worldwide has spurred demand for more effective and targeted therapies, driving investment and research in RNA-based solutions. Moreover, the COVID-19 pandemic has accelerated the adoption of RNA-based vaccines, demonstrating their efficacy and scalability, thereby boosting confidence and investment in this sector. Furthermore, favorable regulatory environments and government initiatives aimed at promoting personalized medicine and precision therapeutics have further fueled market growth. Overall, these factors collectively contribute to the rapid expansion and promising outlook of the RNA-based therapeutics and vaccines market.

Market Restraints

Despite its rapid growth, the RNA-based therapeutics and vaccines market faces several challenges that may restrain its expansion. One significant obstacle is the complexity and cost associated with RNA-based drug development and manufacturing processes. RNA molecules are inherently unstable and prone to degradation, requiring specialized technologies and infrastructure for production and delivery, which can drive up costs and limit scalability. Additionally, concerns regarding safety and efficacy, particularly with newer RNA-based therapies, may hinder widespread adoption among healthcare providers and patients. Moreover, regulatory uncertainties and evolving guidelines for RNA-based products pose challenges for market players seeking approval and commercialization. Furthermore, competition from alternative therapeutic modalities, such as small molecules and biologics, adds to the competitive landscape, requiring companies to differentiate their offerings and demonstrate superior benefits. Overall, addressing these restraints will be essential for unlocking the full potential of the RNA-based therapeutics and vaccines market.

Opportunities

The RNA-based therapeutics and vaccines market presents numerous opportunities for growth and innovation. Firstly, ongoing advancements in RNA technologies, such as mRNA and RNA interference (RNAi), offer the potential to target a wide range of diseases with unprecedented precision and efficacy. This opens doors for the development of novel therapies for conditions that were previously difficult to treat. Additionally, the versatility of RNA-based platforms allows for rapid adaptation to emerging infectious diseases and evolving viral strains, offering a flexible and scalable approach to vaccine development. Moreover, the increasing focus on personalized medicine and precision therapeutics creates opportunities for tailored RNA-based treatments, catering to individual patient needs and genetic profiles. Furthermore, expanding applications beyond traditional diseases to include areas such as oncology, rare genetic disorders, and autoimmune diseases presents new avenues for market expansion.

Additionally, strategic partnerships and collaborations between pharmaceutical companies, biotech firms, and academic institutions can foster innovation and accelerate the development of RNA-based therapeutics and vaccines. Lastly, growing investments in research and development, coupled with supportive regulatory frameworks, provide a conducive environment for market growth and commercialization. Overall, these opportunities underscore the promising outlook for the RNA-based therapeutics and vaccines market, driving continued innovation and investment in the years to come.

Key Questions Answered in Report::

• What is the current size and growth trajectory of the RNA-based therapeutics and vaccines market?
• What are the main drivers fueling market growth, and what are the key challenges hindering expansion?
• What are the emerging trends and opportunities shaping the market landscape?
• What are the different types of RNA-based therapeutics and vaccines available, and what are their respective market shares?
• Which therapeutic areas and applications are driving demand for RNA-based treatments?

Competitive Intelligence and Business Strategy

Competitive intelligence and effective business strategy are paramount in navigating the dynamic landscape of the RNA-based therapeutics and vaccines market. To gain a competitive edge, companies must conduct thorough analyses of market trends, competitor activities, and emerging technologies. This entails monitoring key players' research and development pipelines, partnerships, and regulatory advancements to identify opportunities and threats. Additionally, understanding customer needs and preferences, as well as market segmentation, is crucial for tailoring product offerings and targeting specific market segments effectively.

Formulating a robust business strategy involves leveraging strengths, such as technological expertise and intellectual property, to differentiate products and capture market share. Companies should prioritize investments in research and development to drive innovation and expand their product portfolios. Strategic partnerships and collaborations with academic institutions, biotech firms, and pharmaceutical companies can facilitate access to complementary technologies and accelerate product development timelines.

Key Companies Profiled:

• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma Corp.
• Arrowhead Pharmaceuticals, Inc.
• BioNTech AG
• CureVac AG
• Dicerna Pharmaceuticals, Inc.
• Regulus Therapeutics, Inc.
• Marina Biotech, Inc.
• miRagen Therapeutics
• Moderna Therapeutics, Inc.
• Quark Pharmaceuticals, Inc.
• Santaris Pharma A/S (A Roche Company)
• Sylentis S.A.

Key Segments Covered in RNA-based Therapeutics and Vaccines Market

RNA-based Therapeutics and Vaccines Market by Type of Product

• Workstations
• Reagents and Consumables
• Kits (RNA sample preparation and DNA sample preparation)

RNA-based Therapeutics and Vaccines Market by Application

• Research Applications
• Diagnostic Testing
• Clinical Testing

RNA-based Therapeutics and Vaccines Market by End User

• Diagnostic Centers
• Hospitals
• Academic & Research Institutes
• Forensic Science Laboratories
• CROs (Contract Research Organizations)

RNA-based Therapeutics and Vaccines Market by Region

• North America RNA-based Therapeutics and Vaccines Market
• Latin America RNA-based Therapeutics and Vaccines Market
• Europe RNA-based Therapeutics and Vaccines Market
• Asia-Pacific RNA-based Therapeutics and Vaccines Market
• Middle East & Africa (MEA) RNA-based Therapeutics and Vaccines Market

Table of Contents

1. Executive Summary

• 1.1. Market Overview
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations

2. Market Introduction

• 2.1. Market Definition
• 2.2. Market Taxonomy

3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis

• 3.1. Macro-Economic Factors
• 3.2. Opportunity Analysis

4. Market Background

• 4.1. Regulatory Scenario
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunity Analysis
• 4.3. Pipeline Assessment

5. Gross Domestic Product by Region & Country, 2006 - 2023

6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2024-2031

• 6.1. Introduction
• 6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2024-2031
  • 6.2.1. U.S.
  • 6.2.2. Canada
• 6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2024-2031
  • 6.3.1. RNA-based Therapeutics
    • 6.3.1.1. siRNA
    • 6.3.1.2. miRNA
  • 6.3.2. RNA-based Vaccines
    • 6.3.2.1. mRNA
• 6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2024-2031
  • 6.4.1. Oncology
  • 6.4.2. Immunology
  • 6.4.3. Ophthalmology
  • 6.4.4. Cardiovascular Diseases
  • 6.4.5. Infectious Diseases
  • 6.4.6. Genetic Diseases
  • 6.4.7. Others
• 6.5. Drivers and Restraints - Impact Analysis

7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2024-2031

• 7.1. Introduction
• 7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2024-2031
  • 7.2.1. RNA-based Therapeutics
    • 7.2.1.1. siRNA
    • 7.2.1.2. miRNA
  • 7.2.2. RNA-based Vaccines
    • 7.2.2.1. mRNA
• 7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2024-2031
  • 7.3.1. Oncology
  • 7.3.2. Immunology
  • 7.3.3. Ophthalmology
  • 7.3.4. Cardiovascular Diseases
  • 7.3.5. Infectious Diseases
  • 7.3.6. Genetic Diseases
  • 7.3.7. Others
• 7.4. Drivers and Restraints - Impact Analysis

8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2024-2031

• 8.1. Introduction
• 8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2024-2031
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Russia
  • 8.2.7. Rest of Europe
• 8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2024-2031
  • 8.3.1. RNA-based Therapeutics
    • 8.3.1.1. siRNA
    • 8.3.1.2. miRNA
  • 8.3.2. RNA-based Vaccines
    • 8.3.2.1. mRNA
• 8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2024-2031
  • 8.4.1. Oncology
  • 8.4.2. Immunology
  • 8.4.3. Ophthalmology
  • 8.4.4. Cardiovascular Diseases
  • 8.4.5. Infectious Diseases
  • 8.4.6. Genetic Diseases
  • 8.4.7. Others
• 8.5. Drivers and Restraints - Impact Analysis

9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2024-2031

• 9.1. Introduction
• 9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2024-2031
  • 9.2.1. China
  • 9.2.2. Japan
  • 9.2.3. Australia & New Zealand
  • 9.2.4. Rest of APAC
• 9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2024-2031
  • 9.3.1. RNA-based Therapeutics
    • 9.3.1.1. siRNA
    • 9.3.1.2. miRNA
  • 9.3.2. RNA-based Vaccines
    • 9.3.2.1. mRNA
• 9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2024-2031
  • 9.4.1. Oncology
  • 9.4.2. Immunology
  • 9.4.3. Ophthalmology
  • 9.4.4. Cardiovascular Diseases
  • 9.4.5. Infectious Diseases
  • 9.4.6. Genetic Diseases
  • 9.4.7. Others
• 9.5. Drivers and Restraints - Impact Analysis

10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2024-2031

• 10.1. Introduction
• 10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2024-2031
  • 10.2.1. RNA-based Therapeutics
    • 10.2.1.1. siRNA
    • 10.2.1.2. miRNA
  • 10.2.2. RNA-based Vaccines
    • 10.2.2.1. mRNA
• 10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2024-2031
  • 10.3.1. Oncology
  • 10.3.2. Immunology
  • 10.3.3. Ophthalmology
  • 10.3.4. Cardiovascular Diseases
  • 10.3.5. Infectious Diseases
  • 10.3.6. Genetic Diseases
  • 10.3.7. Others
• 10.4. Drivers and Restraints - Impact Analysis

11. Competition Analysis

• 11.1. Competition Dashboard

12. Company Profiles

• 12.1. Company Deep Dive
  • 12.1.1. Alnylam Pharmaceuticals, Inc.
  • 12.1.2. Arbutus Biopharma Corp.
  • 12.1.3. Arrowhead Pharmaceuticals, Inc.
  • 12.1.4. BioNTech AG
  • 12.1.5. CureVac AG
  • 12.1.6. Dicerna Pharmaceuticals, Inc.
  • 12.1.7. Regulus Therapeutics, Inc.
  • 12.1.8. Marina Biotech, Inc.
  • 12.1.9. miRagen Therapeutics
  • 12.1.10. Moderna Therapeutics, Inc.
  • 12.1.11. Quark Pharmaceuticals, Inc.
  • 12.1.12. Santaris Pharma A/S (A Roche Company)
  • 12.1.13. Sylentis S.A.

13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2024-2031, By Region

• 13.1. Introduction/Key Findings
• 13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2024-2031
  • 13.2.1. North America
  • 13.2.2. Latin America
  • 13.2.3. Europe
  • 13.2.4. Asia Pacific Excluding China
  • 13.2.5. Middle East & Africa
  • 13.2.6. China
• 13.3. Market Attractiveness Analysis By Region

14. Global Product Opportunity Assessment 2024-2031, By Product Type

• 14.1. Introduction/Key Findings
• 14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2024-2031
  • 14.2.1. RNA-based Therapeutics
    • 14.2.1.1. siRNA
    • 14.2.1.2. miRNA
  • 14.2.2. RNA-based Vaccines
    • 14.2.2.1. mRNA
• 14.3. Market Attractiveness Analysis By Product Type

15. Global Product Opportunity Assessment 2024-2031, By Indication Type

• 15.1. Introduction/Key Findings
• 15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2024-2031
  • 15.2.1. Oncology
  • 15.2.2. Immunology
  • 15.2.3. Ophthalmology
  • 15.2.4. Cardiovascular Diseases
  • 15.2.5. Infectious Diseases
  • 15.2.6. Genetic Diseases
  • 15.2.7. Others
• 15.3. Market Attractiveness Analysis By Indication

16. Global Product Opportunity Assessment 2024-2031

• 16.1. Market Opportunity Assessment By All Segment
• 16.2. Absolute $ Opportunity

17. Assumption & Acronyms Used

18. Research Methodology